DK2356270T3 - Kombinatoriske antistofbiblioteker og anvendelser deraf - Google Patents

Kombinatoriske antistofbiblioteker og anvendelser deraf Download PDF

Info

Publication number
DK2356270T3
DK2356270T3 DK09748671.6T DK09748671T DK2356270T3 DK 2356270 T3 DK2356270 T3 DK 2356270T3 DK 09748671 T DK09748671 T DK 09748671T DK 2356270 T3 DK2356270 T3 DK 2356270T3
Authority
DK
Denmark
Prior art keywords
antibody libraries
combinatorial antibody
combinatorial
libraries
antibody
Prior art date
Application number
DK09748671.6T
Other languages
Danish (da)
English (en)
Inventor
Vaughn Smider
James Graziano
Helen Hongyuan Mao
Byeong Doo Song
Tyson Chase
Omar Bazirgan
Original Assignee
Fabrus Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabrus Llc filed Critical Fabrus Llc
Application granted granted Critical
Publication of DK2356270T3 publication Critical patent/DK2356270T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/08—Liquid phase synthesis, i.e. wherein all library building blocks are in liquid phase or in solution during library creation; Particular methods of cleavage from the liquid support
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Structural Engineering (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
DK09748671.6T 2008-11-07 2009-11-04 Kombinatoriske antistofbiblioteker og anvendelser deraf DK2356270T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19876408P 2008-11-07 2008-11-07
US21120409P 2009-03-25 2009-03-25
PCT/US2009/063299 WO2010054007A1 (en) 2008-11-07 2009-11-04 Combinatorial antibody libraries and uses thereof

Publications (1)

Publication Number Publication Date
DK2356270T3 true DK2356270T3 (da) 2016-12-12

Family

ID=41508157

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09748671.6T DK2356270T3 (da) 2008-11-07 2009-11-04 Kombinatoriske antistofbiblioteker og anvendelser deraf

Country Status (7)

Country Link
US (4) US9403904B2 (OSRAM)
EP (2) EP2356270B1 (OSRAM)
JP (4) JP5882058B2 (OSRAM)
AU (4) AU2009313551B2 (OSRAM)
CA (2) CA2742968C (OSRAM)
DK (1) DK2356270T3 (OSRAM)
WO (2) WO2010054010A1 (OSRAM)

Families Citing this family (205)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9567396B2 (en) 2006-03-07 2017-02-14 Evonik Degussa Gmbh Notch inhibition in the prevention of vein graft failure
HUE028379T2 (en) 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
JP5591691B2 (ja) 2007-05-22 2014-09-17 アムジエン・インコーポレーテツド 生物活性を有する融合タンパク質を作製するための組成物及び方法
EA201001467A1 (ru) 2008-03-14 2011-06-30 Биокон Лимитед Моноклональное антитело и способ его использования
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
US8734796B2 (en) 2009-03-20 2014-05-27 Amgen Inc. Carrier immunoglobulins
US20120100999A1 (en) * 2009-04-20 2012-04-26 University Health Network Prognostic gene expression signature for squamous cell carcinoma of the lung
AU2010252939B2 (en) 2009-05-29 2014-06-26 Morphosys Ag A collection and methods for its use
TWI513465B (zh) * 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
ES2895226T3 (es) 2009-10-16 2022-02-18 Mereo Biopharma 5 Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos
EP2493497A4 (en) 2009-11-01 2013-07-24 Brigham & Womens Hospital NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME
WO2011056997A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US10016620B2 (en) * 2010-02-04 2018-07-10 Procept Biorobotics Incorporation Tissue sampling and cancer treatment apparatus
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
DK2505654T4 (da) 2010-02-08 2020-07-27 Regeneron Pharma Mus med fælles letkæde
JP6266343B2 (ja) 2010-07-16 2018-01-24 アディマブ， エルエルシー 抗体ライブラリー
RU2598711C2 (ru) * 2010-07-22 2016-09-27 Те Риджентс Оф Те Юниверсити Оф Калифорния Антитело к противоопухолевому антигену и способы применения
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
EA201370076A1 (ru) 2010-09-22 2013-08-30 Амген Инк. Иммуноглобулины-переносчики и их применение
EP2640742B1 (en) 2010-11-19 2018-08-15 MorphoSys AG A collection of antibody sequences its use
US20160272697A2 (en) * 2011-04-28 2016-09-22 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Neutralizing Antibodies to Nipah and Hendra Virus
DK2702146T3 (en) * 2011-04-28 2019-03-11 Univ Leland Stanford Junior IDENTIFICATION OF POLYNUCLEOTIDES CONNECTED WITH A SAMPLE
KR101641057B1 (ko) 2011-05-04 2016-07-20 오메로스 코포레이션 Masp-2 의존적 보체 활성화를 억제하는 조성물
KR101629073B1 (ko) * 2011-06-15 2016-06-09 에프. 호프만-라 로슈 아게 항-인간 에리스로포이에틴 수용체 항체 및 이의 사용 방법
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
CN103890246A (zh) 2011-08-18 2014-06-25 亲和生物科学公司 可溶性多肽
PT2758073T (pt) 2011-09-23 2019-02-01 Oncomed Pharm Inc Agentes de ligação a vegf/dll4 e utilizações dos mesmos
AU2012332587B2 (en) 2011-11-01 2017-02-23 Bionomics, Inc. Antibodies and methods of treating cancer
AU2012332588B2 (en) 2011-11-01 2017-09-07 Bionomics, Inc. Methods of blocking cancer stem cell growth
WO2013106485A2 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
JP2015509091A (ja) 2012-01-09 2015-03-26 ザ スクリプス リサーチ インスティテュート ヒト化抗体
HUE056335T2 (hu) 2012-01-31 2022-02-28 Regeneron Pharma ASIC1-ellenes antitestek és alkalmazásaik
WO2013131074A1 (en) * 2012-03-02 2013-09-06 Diogenix, Inc. Methods and reagents for evaluating autoimmune disease and determining antibody repertoire
CA2866612C (en) 2012-03-08 2018-01-16 Halozyme, Inc. Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
CN104994872B (zh) 2012-06-21 2018-09-14 索伦托治疗有限公司 与igf1r结合的抗原结合蛋白
KR101535341B1 (ko) * 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
US9777067B2 (en) 2012-09-27 2017-10-03 Massachusetts Institute Of Technology HER2- and VEGF-A-binding proteins with enhanced stability
US9309318B2 (en) * 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
EP2914961A4 (en) * 2012-10-31 2016-04-20 Oncomed Pharm Inc METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4
BR112015010240A2 (pt) * 2012-11-06 2017-08-22 Medimmune Ltd Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas
US10407503B2 (en) * 2012-11-30 2019-09-10 The Regents Of The University Of California Fully human antibodies and fragments recognizing human c-Met
KR102233664B1 (ko) 2012-12-05 2021-04-02 노파르티스 아게 Epo를 표적화하는 항체에 대한 조성물 및 방법
SG11201505663YA (en) * 2013-01-24 2015-08-28 Scripps Korea Antibody Inst Protein combination-based fv library, and preparation method therefor
DK2989239T4 (da) * 2013-04-25 2025-04-07 Sutro Biopharma Inc Selektion af Fab-fragmenter ved anvendelse af ribosomfremvisningsteknologi
WO2014176439A1 (en) 2013-04-25 2014-10-30 Sutro Biopharma, Inc. The use of lambda-gam protein in ribosomal display technology
RU2539752C2 (ru) * 2013-05-23 2015-01-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО И АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ (Fab), СВЯЗЫВАЮЩИЕСЯ С ИНТЕРФЕРОНОМ- γ ЧЕЛОВЕКА, ФРАГМЕНТЫ ДНК, КОДИРУЮЩИЕ УКАЗАННОЕ АНТИТЕЛО И АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ, КЛЕТКА, ТРАНСФОРМИРОВАННАЯ ФРАГМЕНТОМ ДНК, И СПОСОБ ПОЛУЧЕНИЯ УКАЗАННОГО АНТИТЕЛА И АНТИГЕНСВЯЗЫВАЮЩЕГО ФРАГМЕНТА
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
US10640574B2 (en) 2013-07-18 2020-05-05 Taurus Biosciences, Llc Humanized antibodies with ultralong complementary determining regions
LT3052192T (lt) * 2013-10-02 2020-12-10 Medimmune, Llc Neutralizuojantys antikūnai prieš gripą a ir jų naudojimas
WO2015057906A1 (en) * 2013-10-16 2015-04-23 Janssen Biotech, Inc. Cd200 receptor 1 agonists
GB201403775D0 (en) * 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN106103730B (zh) 2014-03-14 2021-06-08 豪夫迈·罗氏有限公司 用于分泌异源多肽的方法和组合物
BR112016021572A2 (pt) 2014-03-21 2017-10-03 Regeneron Pharma Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
CN112759650B (zh) 2014-04-03 2024-10-01 Igm生物科学股份有限公司 修饰的j链
EP3126397B1 (en) * 2014-04-04 2020-01-29 Bionomics, Inc. Humanized antibodies that bind lgr5
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
ES2782083T3 (es) * 2014-06-24 2020-09-10 Procept Biorobotics Corp Aparato de muestreo de tejidos y tratamiento del cáncer
AU2015289805B2 (en) 2014-07-15 2020-06-25 Humabs Biomed Sa Neutralizing anti-influenza B antibodies and uses thereof
EA201790489A1 (ru) * 2014-08-29 2017-08-31 Сорренто Терапьютикс, Инк. ТЕРАПЕВТИЧЕСКИЕ СРЕДСТВА НА ОСНОВЕ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ OprF И OprI
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
CN107405397B (zh) 2014-10-27 2020-08-25 新加坡科技研究局 抗tim-3抗体
AU2015338974B2 (en) 2014-10-31 2021-08-26 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
EA201791050A1 (ru) 2014-11-14 2017-09-29 Новартис Аг Конъюгаты антител и лекарственных средств
EP3026060A1 (en) * 2014-11-26 2016-06-01 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for CD45R0
EP3227432B1 (en) 2014-12-05 2023-10-11 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
KR102701479B1 (ko) 2014-12-05 2024-09-03 메모리얼 슬로안 케터링 캔서 센터 B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법
EP3246434A1 (en) * 2015-01-13 2017-11-22 Ewha University-Industry Collaboration Foundation Method for preparing novel antibody library and library prepared thereby
CN108025063A (zh) 2015-03-10 2018-05-11 索伦托治疗有限公司 结合psma的抗体治疗剂
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
CN107921122B (zh) 2015-04-08 2021-08-10 索伦托药业有限公司 与cd38结合的抗体治疗剂
PT3283524T (pt) 2015-04-17 2023-06-05 Amgen Res Munich Gmbh Construções de anticorpos biespecíficos para cdh3 e cd3
PH12017502013B1 (en) 2015-05-07 2022-07-22 Agenus Inc Anti-ox40 antibodies and methods of use thereof
EP3297663B1 (en) 2015-05-18 2025-11-12 Agensys, Inc. Antibodies that bind to axl proteins
WO2016187354A1 (en) * 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
PL3303384T3 (pl) 2015-06-01 2022-01-03 Medimmune, Llc Neutralizujące cząsteczki wiążące przeciw grypie i ich zastosowania
WO2017008049A1 (en) * 2015-07-08 2017-01-12 The Board Of Trustees Of The Leland Stanford Junior University Heterotypic antibodies specific for human rotavirus
CN107922975B (zh) 2015-08-12 2022-06-28 诺华股份有限公司 治疗眼科病症的方法
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
ES2996834T3 (en) 2015-09-30 2025-02-13 Igm Biosciences Inc Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
TWI752920B (zh) 2015-10-12 2022-01-21 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
EP3184547A1 (en) * 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
TWI726936B (zh) 2015-11-10 2021-05-11 美商麥迪紐有限責任公司 對asct2具專一性之結合分子及其用途
EP3383914A4 (en) * 2015-12-02 2019-10-30 Agenus Inc. ANTI-OX40 ANTIBODIES AND METHOD OF USE THEREOF
SG11201804265XA (en) 2015-12-02 2018-06-28 Agenus Inc Antibodies and methods of use thereof
WO2017096182A1 (en) * 2015-12-03 2017-06-08 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
CN106939047B (zh) 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
CN105693821A (zh) * 2016-01-08 2016-06-22 中国药科大学 与人血管内皮生长因子受体-3(vegfr-3)蛋白特异性结合的多肽，其筛选方法，鉴定和用途
EA201891299A1 (ru) 2016-01-08 2019-01-31 Аимм Терапьютикс Б.В. Терапевтические антитела к cd9
CA3010313A1 (en) 2016-01-13 2017-07-20 Medimmune, Llc Method of treating influenza a
JP7022067B2 (ja) * 2016-01-14 2022-02-17 メモリアル スローン ケタリング キャンサー センター Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体
AU2017239038B2 (en) 2016-03-22 2024-06-27 Bionomics Inc Administration of an anti-LGR5 monoclonal antibody
KR102574810B1 (ko) 2016-04-15 2023-09-08 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 습성 연령 관련 황반 변성의 치료를 위한 조성물
WO2017218371A1 (en) * 2016-06-14 2017-12-21 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
CA3026474A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
CN110291402B (zh) 2016-06-27 2023-09-01 朱诺治疗学股份有限公司 鉴定肽表位的方法、结合此类表位的分子和相关用途
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
US11168148B2 (en) 2016-09-07 2021-11-09 The Regents Of The University Of California Antibodies to oxidation-specific epitopes
CN118005799A (zh) * 2016-09-23 2024-05-10 马伦戈治疗公司 包含λ轻链和κ轻链的多特异性抗体分子
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
WO2018075621A1 (en) * 2016-10-19 2018-04-26 Vanderbilt University Human orthopoxvirus antibodies and methods of use therefor
US20190324040A1 (en) * 2016-10-29 2019-10-24 University Of Miami Zika virus antibodies
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
EP4613772A3 (en) 2016-11-08 2025-12-24 Regeneron Pharmaceuticals, Inc. Antigen-binding proteins that antagonize leptin receptor
CA3041340A1 (en) * 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
TW201832778A (zh) * 2016-11-10 2018-09-16 美商麥迪紐有限責任公司 對ａｓｃｔ２具有特異性的結合分子及其用途
MA46952A (fr) 2016-12-01 2019-10-09 Regeneron Pharma Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet
KR102599557B1 (ko) * 2016-12-19 2023-11-07 펀다시오 프리바다 인스티튜시오 카탈라나 드 르세르카 아이 에스투디스 아반카츠 Lif에 대한 항체 및 이의 용도
JP2020506971A (ja) 2017-02-08 2020-03-05 ドラゴンフライ セラピューティクス， インコーポレイテッド ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用
CN108456250B (zh) * 2017-02-17 2025-11-28 恺兴生命科技(上海)有限公司 靶向il-13ra2的抗体及其应用
WO2018151836A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
SG11201907646YA (en) 2017-02-20 2019-09-27 Dragonfly Therapeutics Inc Proteins binding her2, nkg2d and cd16
CN110637031B (zh) * 2017-03-04 2024-04-16 湘潭腾华生物科技有限公司 程序性死亡蛋白1(pd-1)的重组抗体及其用途
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
US10296425B2 (en) 2017-04-20 2019-05-21 Bank Of America Corporation Optimizing data processing across server clusters and data centers using checkpoint-based data replication
WO2019018525A1 (en) * 2017-07-20 2019-01-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. CHIMERIC ANTIGENIC RECEPTORS BINDING TO CD123
SG10202111869SA (en) * 2017-07-31 2021-11-29 Trishula Therapeutics Inc Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
WO2019036688A1 (en) * 2017-08-18 2019-02-21 Gritstone Oncology, Inc. ANTIGEN BINDING PROTEINS TARGETING SHARED ANTIGENS
PL3703750T3 (pl) 2017-11-01 2025-04-07 Juno Therapeutics, Inc. Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy
MA49911A (fr) 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
MX2020004568A (es) 2017-11-06 2020-10-05 Juno Therapeutics Inc Combinación de una terapia celular y un inhibidor de gamma secretasa.
US11034951B2 (en) 2017-11-20 2021-06-15 Nantbio, Inc. mRNA display antibody library and methods
ES2969081T3 (es) * 2017-11-20 2024-05-16 Nantbio Inc Una biblioteca de anticuerpos de presentación de ARNm y métodos
CN111542540A (zh) 2017-12-18 2020-08-14 瑞泽恩制药公司 结合瘦蛋白受体和/或gp130的双特异性抗原结合分子及其使用方法
CN117946267A (zh) 2017-12-19 2024-04-30 瑟罗泽恩奥普瑞汀公司 抗卷曲蛋白抗体和使用方法
AU2018393073B2 (en) 2017-12-19 2025-09-18 Surrozen Operating, Inc. Wnt surrogate molecules and uses thereof
CA3085785A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Anti-lrp5/6 antibodies and methods of use
WO2019143884A1 (en) * 2018-01-19 2019-07-25 Vanderbilt University Conserved hiv antibody clonotypes and methods of use
FI3749346T3 (fi) 2018-02-08 2024-09-04 Dragonfly Therapeutics Inc Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
PE20210375A1 (es) 2018-02-08 2021-03-02 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales
MX2020008684A (es) 2018-02-20 2020-12-07 Dragonfly Therapeutics Inc Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso.
JP7362636B2 (ja) 2018-03-05 2023-10-17 ヤンセン ファーマシューティカ エヌ．ベー． 抗ｐｈｆ－タウ抗体及びその使用
CR20200466A (es) 2018-03-13 2020-11-11 Tusk Therapeutics Ltd Agentes anticuerpos anti-cd25
HRP20250986T1 (hr) 2018-04-06 2025-10-24 Regeneron Pharmaceuticals, Inc. Antitijelo agonista leptinskog receptora za upotrebu u povećanju koštane mase kod osobe koja pati od metaboličke disfunkcije ili hipoleptinemije
EP3553082A1 (en) * 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Brain natriuretic peptide engrafted antibodies
EP3553081A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Atrial natriuretic peptide engrafted antibodies
EP3553079A1 (en) * 2018-04-12 2019-10-16 Bayer Aktiengesellschaft C-type natriuretic peptide engrafted antibodies
US12036242B2 (en) 2018-07-05 2024-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T cells that target B-cell antigens
US10954508B2 (en) * 2018-07-08 2021-03-23 Specifica Inc. Antibody libraries with maximized antibody developability characteristics
CN110713537B (zh) * 2018-07-13 2023-04-21 江苏怀瑜药业有限公司 一种sema4d抗体及其制备方法和应用
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
JP7482363B2 (ja) 2018-08-08 2024-05-14 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及び腫瘍関連抗原に結合するタンパク質
US12384851B2 (en) 2018-08-08 2025-08-12 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
CN112930393A (zh) 2018-08-28 2021-06-08 福瑞德哈金森癌症研究中心 结合诱导的Notch信号传导的过继T细胞疗法的方法和组合物
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
CN109553680B (zh) * 2018-12-12 2021-06-01 广州市第八人民医院 一种单克隆抗体ZKns4B8及其应用
CN113226371B (zh) * 2018-12-28 2025-05-30 协和麒麟株式会社 与TfR结合的双特异性抗体
KR102736548B1 (ko) * 2019-01-31 2024-12-02 난트바이오 인코포레이티드 Mrna 디스플레이 항체 라이브러리 및 방법
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
WO2020205775A1 (en) * 2019-03-29 2020-10-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Antibodies against programmed cell death protein 1 (pd1) and uses thereof
WO2020219774A1 (en) * 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Anthracycline antibody-drug conjugates and uses thereof
AU2020279224B2 (en) * 2019-05-21 2024-12-05 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
JP7744011B2 (ja) 2019-06-07 2025-09-25 スクライブ・セラピューティクス・インコーポレイテッド 操作されたｃａｓｘシステム
WO2020247883A2 (en) * 2019-06-07 2020-12-10 Scribe Therapeutics Inc. Deep mutational evolution of biomolecules
AU2020290579A1 (en) 2019-06-14 2021-12-16 Dana-Farber Cancer Institute, Inc. Antibodies against MUC1 and methods of use thereof
AU2020300618A1 (en) * 2019-07-02 2022-01-27 Surrozen Operating, Inc. Monospecific anti-frizzled antibodies and methods of use
WO2021011673A2 (en) * 2019-07-16 2021-01-21 Ming Jin Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease
WO2021061829A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for crth2
AU2020355027A1 (en) * 2019-09-23 2022-04-21 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
IL292419A (en) * 2019-10-24 2022-06-01 Prometheus Biosciences Inc Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
CN115443140A (zh) * 2020-04-02 2022-12-06 苏州恒康生命科学有限公司 人ror-1抗体和抗ror-1-car-t细胞
BR112022021789A2 (pt) 2020-04-27 2023-03-07 Twist Bioscience Corp Bibliotecas de ácido nucléico variantes para coronavírus
TW202208428A (zh) 2020-05-06 2022-03-01 美商蜻蜓醫療公司 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質
US20240002476A1 (en) * 2020-05-20 2024-01-04 The Trustees Of Columbia University In The City Of New York Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
CN111748033B (zh) * 2020-05-27 2021-02-02 江苏省疾病预防控制中心(江苏省公共卫生研究院) 一种与新型冠状病毒np蛋白结合的分离抗体、包含其的检测试剂盒
EP4165171A4 (en) 2020-06-12 2025-03-26 Nkarta, Inc. GENETICALLY MODIFIED NATURAL KILLER CELLS FOR CD70-DIRECTED CANCER IMMUNOTHERAPY
EP4154910A4 (en) * 2020-06-30 2024-09-11 Harbour Biomed (Shanghai) Co., Ltd Binding protein having h2l2 and hcab structures
JP2023537386A (ja) * 2020-08-10 2023-08-31 インテグラル・モレキュラー・インコーポレイテッド 抗体ライブラリーを作製するための方法および組成物ならびにそれから単離された抗体
WO2022087393A1 (en) * 2020-10-23 2022-04-28 Icahn School Of Medicine At Mount Sinai Sars-cov-2 antibodies and uses thereof
EP4256054A1 (en) 2020-12-03 2023-10-11 Scribe Therapeutics Inc. Engineered class 2 type v crispr systems
KR20230118134A (ko) * 2020-12-04 2023-08-10 이퀼리엄 아이엔씨 CD6 high 세포 선택적 표적화 및 T eff 세포의 활성감소 방법
MX2023008188A (es) * 2021-01-11 2023-09-28 Adimab Llc Variante de dominios ch1 y variante de dominios cl modificadas geneticamente para el emparejamiento preferencial a cadenas y anticuerpos multiespecíficos que comprenden las mismas.
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
US20240327503A1 (en) * 2021-03-12 2024-10-03 Jimmy Dale GOLLIHAR Sars-cov-2 neutralizing antibodies and uses thereof
US12258406B2 (en) 2021-03-24 2025-03-25 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
US11655290B2 (en) 2021-06-17 2023-05-23 Atreca, Inc. Anti-CSP antibodies
US20250319185A1 (en) * 2021-07-12 2025-10-16 Nkarta, Inc. Bcma-directed cellular immunotherapy compositions and methods
WO2023004431A2 (en) * 2021-07-23 2023-01-26 The Trustees Of Columbia University In The City Of New York Characterization of potent and broadly neutralizing monoclonal antibodies against sars-cov-2, its variants, and related coronaviruses and methods of use
JP2024527029A (ja) 2021-07-29 2024-07-19 セファロン リミティド ライアビリティ カンパニー 抗ｐａｃａｐ抗体の組成物及び方法
AU2022333321A1 (en) 2021-08-27 2024-04-11 Janssen Biotech, Inc. Anti-psma antibodies and uses thereof
MX2024002479A (es) * 2021-08-27 2024-05-28 Janssen Biotech Inc Radioconjugados anti-psma y usos de estos.
CA3228414A1 (en) * 2021-09-02 2023-03-09 Anthony DANIYAN Anti-cd33 antibodies and uses thereof
CA3228546A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Antigen recognizing receptors targeting cd33 and uses thereof
WO2023034950A2 (en) * 2021-09-03 2023-03-09 Icahn School Of Medicine At Mount Sinai Anti-hcmv antibodies and antigen-binding fragments thereof
US20230265217A1 (en) * 2021-10-27 2023-08-24 Twist Bioscience Corporation Multispecific sars-cov-2 antibodies and methods of use
CN116333123A (zh) * 2021-12-22 2023-06-27 宝船生物医药科技(上海)有限公司 抗tnfr2抗体及其用途
CA3245432A1 (en) * 2022-03-04 2023-09-07 Coagulant Therapeutics Corporation Human antibodies directed against activated protein C and their uses
WO2024077104A2 (en) * 2022-10-04 2024-04-11 Mink Therapeutics, Inc. Fibroblast activation protein (fap) car-invariant natural killer t cells and uses thereof
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
CN116514998B (zh) * 2023-05-12 2023-09-15 再少年(北京)生物科技有限公司 一种嵌合抗原受体、嵌合抗原受体-自然杀伤细胞及其在制备抗肿瘤药物中的应用
US20250019426A1 (en) * 2023-07-03 2025-01-16 Uct Bioscience Co., Ltd. Anti-grp78 antibodies and their uses
WO2025015320A2 (en) * 2023-07-12 2025-01-16 Phenomic Ai Anti-cthrc1 t cell engagers and methods of using the same
WO2025049915A1 (en) * 2023-08-31 2025-03-06 Exelixis, Inc. Ilt2 binding agents and uses thereof
US20250101101A1 (en) * 2023-09-01 2025-03-27 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2025081163A1 (en) * 2023-10-13 2025-04-17 GenCART, Inc. Compositions for the treatment of cancer
US20250255980A1 (en) * 2024-02-12 2025-08-14 Mbrace Therapeutics, Inc. Antibody-Drug Conjugates Against the Glucose-regulating Protein 78 (GRP78)
WO2025184137A1 (en) * 2024-02-27 2025-09-04 Adimab, Llc Influenza antibodies and methods of use thereof
CN117986346B (zh) * 2024-04-07 2024-07-26 中国人民解放军军事科学院军事医学研究院 一种tpo模拟肽及其应用
WO2025217041A2 (en) * 2024-04-09 2025-10-16 Absos, Llc Anti-april antibodies
CN120399078A (zh) * 2025-05-08 2025-08-01 上海天泽云泰生物医药有限公司 靶向cd117的纳米抗体及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
JP3127158B2 (ja) 1989-10-05 2001-01-22 オプテイン，インコーポレイティド 新規の遺伝子及びポリペチドの無細胞合成並びに単離
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5866344A (en) 1991-11-15 1999-02-02 Board Of Regents, The University Of Texas System Antibody selection methods using cell surface expressed libraries
US20030036092A1 (en) 1991-11-15 2003-02-20 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
US5965408A (en) 1996-07-09 1999-10-12 Diversa Corporation Method of DNA reassembly by interrupting synthesis
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
US6153410A (en) 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
ATE342358T1 (de) 1997-04-04 2006-11-15 Millennium Biotherapeutics Inc Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen
DE69837601T2 (de) 1997-05-14 2007-12-27 Asahi Kasei Kabushiki Kaisha Neuer hemmer der differentierung
JP2002523018A (ja) 1998-07-27 2002-07-30 アムジエン・インコーポレーテツド デルタ関連ポリペプチド
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US20020102613A1 (en) 1999-05-18 2002-08-01 Hoogenboom Hendricus Renerus Jacobus Mattheus Novel Fab fragment libraries and methods for their use
GB0008419D0 (en) 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
AU784231B2 (en) 2000-06-23 2006-02-23 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use (II)
FR2816319B1 (fr) 2000-11-08 2004-09-03 Millegen Utilisation d'adn polymerase mutagene pour la creation de mutations aleatoires
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US20030022240A1 (en) 2001-04-17 2003-01-30 Peizhi Luo Generation and affinity maturation of antibody library in silico
EP1438402A2 (en) 2001-08-22 2004-07-21 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
WO2003035842A2 (en) 2001-10-24 2003-05-01 Dyax Corporation Hybridization control of sequence variation
WO2003099999A2 (en) 2002-05-20 2003-12-04 Abmaxis, Inc. Generation and selection of protein library in silico
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2005023993A2 (en) * 2003-09-09 2005-03-17 Integrigen, Inc. Methods and compositions for generation of germline human antibody genes
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
AU2006210660B2 (en) 2005-02-01 2011-12-01 Morphosys Ag Libraries and methods for isolating antibodies
CA2627075A1 (en) 2005-11-14 2007-05-18 Bioren, Inc. Antibody ultrahumanization by predicted mature cdr blasting and cohort library generation and screening
WO2007070671A2 (en) 2005-12-16 2007-06-21 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with dll4 antagonists
US20090318308A1 (en) 2006-05-30 2009-12-24 Millegen Highly diversified antibody libraries
US20080014196A1 (en) 2006-06-06 2008-01-17 Genentech, Inc. Compositions and methods for modulating vascular development
AU2007319672B2 (en) 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same
SG174033A1 (en) 2006-08-07 2011-09-29 Regeneron Pharma Therapeutic methods for treating vascular eye disorders with dll4 antagonists
HUE028379T2 (en) * 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
US20080100597A1 (en) 2006-10-25 2008-05-01 Macrovision Corporation Method and apparatus to improve playability in overscan areas of a TV display
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
WO2008091222A1 (en) 2007-01-26 2008-07-31 Bioinvent International Ab Dll4 signaling inhibitors and uses thereof
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf

Also Published As

Publication number Publication date
CA2742968C (en) 2020-06-09
US20120058906A1 (en) 2012-03-08
JP5882058B2 (ja) 2016-03-09
AU2009313560A1 (en) 2010-05-14
US20200399359A1 (en) 2020-12-24
JP2012508017A (ja) 2012-04-05
AU2009313551B2 (en) 2015-12-17
US20160194627A1 (en) 2016-07-07
JP2016127850A (ja) 2016-07-14
EP2356270A1 (en) 2011-08-17
AU2009313560B2 (en) 2016-04-14
WO2010054010A1 (en) 2010-05-14
WO2010054007A1 (en) 2010-05-14
US9221902B2 (en) 2015-12-29
AU2009313551A1 (en) 2010-05-14
EP2356146A1 (en) 2011-08-17
CA2742969A1 (en) 2010-05-14
AU2018201622A1 (en) 2018-03-29
CA2742968A1 (en) 2010-05-14
US9403904B2 (en) 2016-08-02
JP2016040246A (ja) 2016-03-24
US20110318339A1 (en) 2011-12-29
US10774138B2 (en) 2020-09-15
EP2356270B1 (en) 2016-08-24
JP2012508016A (ja) 2012-04-05
AU2016204719A1 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
DK2356270T3 (da) Kombinatoriske antistofbiblioteker og anvendelser deraf
DK3124497T3 (da) Rationelt designede syntetiske antistofbiblioteker og anvendelser deraf
DK2059535T3 (da) Prlr-specifikt antistof og anvendelser deraf
DK2209806T3 (da) Anti-hepcidin-antistoffer og anvendelser deraf
DK2068887T3 (da) SP35-antistoffer og anvendelser heraf
DK1994055T3 (da) Anti-5t4-antistoffer og anvendelser deraf
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK2328931T3 (da) Selektive anti-hepcidin-25-antistoffer og anvendelser deraf
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
DK2283041T3 (da) Humaniserede anti-faktor d-antistoffer og anvendelser deraf
DK2147096T3 (da) Modificerede faktor-VII-polypeptider og anvendelser deraf
DK1904104T3 (da) SP35-antistoffer og anvendelser heraf
PT2537529T (pt) Anticorpos inibidores de loxl2 e suas utilizações
DK2786762T3 (da) Kovalente diabodies og anvendelser deraf
DK2371958T3 (da) HIDTIL UKENDTE siRNA OG FREMGANGSMÅDER TIL ANVENDELSE DERAF
DK2240203T3 (da) Alfa5-beta1-antistoffer og deres anvendelser
DK3211126T3 (da) Fremgangsmåder til dannelse og screening af dna-kodede biblioteker
DK3338790T3 (da) Oligopeptid-forbindelser og anvendelser deraf
DK2252633T3 (da) Anti-TrkA antistoffer og derivater deraf
DK2913344T3 (da) Specifikke bindingsproteiner og anvendelser deraf
DK2907827T3 (da) Humaniserede anti-faktor D-antistoffer og anvendelser deraf
DK3567363T3 (da) Prøvningsindretninger, -fremgangsmåder og reagenser
DK2993186T3 (da) En monoklonal antistof og en fremgangsmåde hertil
IL211552A0 (en) Improved antibody libraries
DK2310356T3 (da) Adamantyl-diamid-derivater og anvendelser deraf